

# ANTICANCER RESEARCH

## International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 30, Number 11, November 2010

### Contents

#### *Experimental Studies*

- MicroRNA-184-Mediated Inhibition of Tumour Growth in an Orthotopic Murine Model of Neuroblastoma. A. TIVNAN, N.H. FOLEY, L. TRACEY, A.M. DAVIDOFF, R.L. STALLINGS (*Dublin, Ireland; Memphis, TN, USA*) ..... 4391
- Remodeling of the Tumor Microenvironment by Combined Treatment with a Novel Radiosensitizer,  $\alpha$ -Sulfoquinovosylmonoacylglycerol ( $\alpha$ -SQMG) and X-irradiation. K. OHTA, H. MURATA, Y. MORI, M. ISHIMA, F. SUGAWARA, K. SAKAGUCHI, M. MIURA (*Tokyo; Chiba, Japan*) ..... 4397
- Impact of the Src Inhibitor Saracatinib on the Metastatic Phenotype of a Fibrosarcoma (KHT) Tumor Model. M. DONG, L. RICE, S. LEPLER, C. PAMPO, D.W. SIEMANN (*Gainesville, FL, USA*) ..... 4405
- Real-time Imaging of Tumor Progression in a Fluorescent Orthotopic Mouse Model of Thyroid Cancer. H.S. TRAN CAO, S. KAUSHAL, C.S. SNYDER, W.M. ONGKEKO, R.M. HOFFMAN, M. BOUVET (*San Diego, CA, USA*) ..... 4415
- Lignans and Norlignans Inhibit Multidrug Resistance Protein 1 (MRP1/ABCC1)-mediated Transport. A. WRÖBEL, P. EKLUND, M. BOBROWSKA-HÄGERSTRAND, H. HÄGERSTRAND (*Wrocław, Poland; Åbo/Turku, Finland*) ..... 4423
- Vitamin D, Calcidiol and Calcitriol Regulate Vitamin D Metabolizing Enzymes in Cervical and Ovarian Cancer Cells. M. KLOSS, D. FISCHER, M. THILL, M. FRIEDRICH, T. CORDES, D. SALEHIN, K. DIEDRICH, F. KÖSTER (*Lübeck; Krefeld, Germany*) ..... 4429

*Contents continued on the back cover*

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005

ISSN (online): 1791-7530

## Editorial Board

- B. B. AGGARWAL**, Houston, TX, USA  
**J. P. ARMAND**, Toulouse, France  
**V. I. AVRAMIS**, Los Angeles, CA, USA  
**R. C. BAST**, Houston, TX, USA  
**G. BAUER**, Freiburg, Germany  
**E. E. BAULIEU**, Le Kremlin-Bicetre, France  
**Y. BECKER**, Jerusalem, Israel  
**E. J. BENZ, Jr.**, Boston, MA, USA  
**J. BERGH**, Stockholm, Sweden  
**D. D. BIGNER**, Durham, NC, USA  
**A. BÖCKING**, Disseldorf, Germany  
**G. BONADONNA**, Milan, Italy  
**F. T. BOSMAN**, Lausanne, Switzerland  
**G. BROICH**, Milan, Italy  
**J. M. BROWN**, Stanford, CA, USA  
**Ø. S. BRULAND**, Oslo, Norway  
**M. M. BURGER**, Basel, Switzerland  
**M. CARBONE**, Honolulu, HI, USA  
**J. CARLSSON**, Uppsala, Sweden  
**A. F. CHAMBERS**, London, ON, Canada  
**P. CHANDRA**, Frankfurt am Main, Germany  
**L. CHENG**, Indianapolis, IN, USA  
**J.-G. CHUNG**, Taichung, Taiwan, ROC  
**E. DE CLERCQ**, Leuven, Belgium  
**W. DE LOECKER**, Leuven, Belgium  
**W. DEN OTTER**, Amsterdam, The Netherlands  
**E. P. DIAMANDIS**, Toronto, ON, Canada  
**G. TH. DIAMANDOPOULOS**, Boston, MA, USA  
**W. EBERT**, Heidelberg, Germany  
**J. A. FERNANDEZ-POL**, Chesterfield, MO, USA  
**I. J. FIDLER**, Houston, TX, USA  
**G. GABBIANI**, Geneva, Switzerland  
**R. GANAPATHI**, Cleveland, OH, USA  
**A. F. GAZDAR**, Dallas, TX, USA  
**A. GIORDANO**, Philadelphia, PA, USA  
**G. GITSCH**, Freiburg, Germany  
**R. H. GOLDFARB**, Princeton, NJ, USA  
**J. W. GORROD**, Colchester, Essex, UK  
**S. HAMMARSTRÖM**, Umeå, Sweden  
**I. HART**, London, UK  
**I. HELLSTRÖM**, Seattle, WA, USA  
**L. HELSON**, Valhalla, NY, USA  
**R. B. HERBERMAN**, Pittsburgh, PA, USA  
**R. M. HOFFMAN**, San Diego, CA, USA  
**C. G. IOANNIDES**, Houston, TX, USA  
**S. C. JHANWAR**, New York, NY, USA  
**J. V. JOHANNESSEN**, Oslo, Norway  
**B. KAINA**, Mainz, Germany  
**B. K. KEPPLER**, Vienna, Austria  
**D. G. KIEBACK**, Dresden, Germany  
**R. KLAPDOR**, Hamburg, Germany  
**U. R. KLEEBERG**, Hamburg, Germany  
**P. KLEIHUES**, Zürich, Switzerland  
**E. KLEIN**, Stockholm, Sweden  
**S. VON KLEIST**, Freiburg, Germany  
**S. D. KOTTARIDIS**, Athens, Greece
- G. R. F. KRUEGER**, Köln, Germany  
**D. W. KUFE**, Boston, MA, USA  
**Pat M. KUMAR**, Manchester, UK  
**Shant KUMAR**, Manchester, UK  
**M. KUROKI**, Fukuoka, Japan  
**O. D. LAERUM**, Bergen, Norway  
**F. J. LEJEUNE**, Lausanne, Switzerland  
**L. F. LIU**, Piscataway, NJ, USA  
**D. M. LOPEZ**, Miami, FL, USA  
**E. LUNDGREN**, Umeå, Sweden  
**H. T. LYNCH**, Omaha, NE, USA  
**J. MARESCAUX**, Strasbourg, France  
**J. MARK**, Skövde, Sweden  
**J. F. MARSHALL**, London, UK  
**D. MEDINA**, Houston, TX, USA  
**S. MITRA**, Galveston, TX, USA  
**M. MUELLER**, Heidelberg, Germany  
**F. M. MUGGIA**, New York, NY, USA  
**M. J. MURPHY, Jr.**, Dayton, OH, USA  
**R. NARAYANAN**, Boca Raton, FL, USA  
**K. NILSSON**, Uppsala, Sweden  
**J. F. NOVAK**, Lewisburg, PA, USA  
**S. PATHAK**, Houston, TX, USA  
**S. PESTKA**, Piscataway, NJ, USA  
**G. J. PILKINGTON**, Portsmouth, UK  
**C. D. PLATSOUKAS**, Norfolk, VA, USA  
**F. PODO**, Rome, Italy  
**A. POLLIACK**, Jerusalem, Israel  
**M. F. RAJEWSKY**, Essen, Germany  
**G. REBEL**, Strasbourg, France  
**M. RIGAUD**, Limoges, France  
**U. RINGBORG**, Stockholm, Sweden  
**M. ROSELLI**, Rome, Italy  
**A. SCHAUER**, Göttingen, Germany  
**M. SCHNEIDER**, Wuppertal, Germany  
**A. SETH**, Toronto, ON, Canada  
**G. V. SHERBET**, Newcastle-upon-Tyne, UK  
**G.-I. SOMA**, Tokushima, Japan  
**G. S. STEIN**, Worcester, MA, USA  
**T. STIGBRAND**, Umeå, Sweden  
**D. TARIN**, La Jolla, CA, USA  
**T. M. THEOPHANIDES**, Athens, Greece  
**B. TOTH**, Omaha, NE, USA  
**P. M. UELAND**, Bergen, Norway  
**P. T. VIHKO**, Oulu, Finland  
**M. VOLM**, Heidelberg, Germany  
**G. WEBER**, Indianapolis, IN, USA  
**B. WESTERMARK**, Uppsala, Sweden  
**B. ZUMOFF**, New York, NY, USA
- J. G. DELINASSIOS**, Athens, Greece  
Managing Editor and Executive Publisher  
**S. AZOUDIS**, Surrey, BC, Canada  
Assistant Managing Editor  
**E. ILIADIS**, Athens, Greece  
Production Editor

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

E-mails: Editorial Office: journals@iiaar-anticancer.org  
Managing Editor: editor@iiaar-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research.

For more information about ANTICANCER RESEARCH, IAR and the Conferences, please visit the IAR website: [www.iiaar-anticancer.org](http://www.iiaar-anticancer.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

**Copyright:** On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

**Annual Subscription Rates 2010 per volume:** Institutional subscription Euro 1,650.00 - online; Euro 1,670.00 - print; Euro 1,700.00 - print & online. Personal subscription Euro 780.00 - online; Euro 800.00 - print; Euro 830 - print & online. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-29, 1981-2009) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the Publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece, and should be sent to the Editorial Office.

**Advertising:** All correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.


Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2010 \$2.00 +0.40.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2010, International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.  
PHOTOCOMPOSITION BY IAR  
PRINTED BY ENTYPPO, ATHENS, GREECE  
PRINTED ON ACID-FREE PAPER

# New Nanoscale Human Angiogenesis Assay



**Top:** Optical image of highly uniform angiogenesis antibody features in one nanoscale sub-array. **Bottom:** Fluorescent image showing ultrasensitive NanoInk assay results using 111 pg/ml of recombinant human antigens.

## Easily Detect Low-Abundance Proteins

Until now, detecting low-abundance angiogenesis proteins has been difficult. NanoInk's revolutionary nanoarray technology overcomes the hurdles of conventional platforms, giving you assay sensitivity in the 100 femtograms/ml range. With the nanoscale Human Angiogenesis Assay, you can simultaneously evaluate ANG, EGF, FGF, G-CSF, HGF, IL8, Leptin, PIGF, VEGF, and HB-EGF within 6 hours. And the ultra low sample requirements of this miniaturized immunoassay decrease reagent costs and conserve precious sample.

**Experience the power of nanoscale.** Take advantage of the Human Angiogenesis Assay special introductory price of \$250 now.

Find out more at: [www.nanoink.net/nanobio](http://www.nanoink.net/nanobio) | 847-679-3432.



**nANOINK** INC.  
Nano BioDiscovery

© 2010 NanoInk, Inc. All rights reserved.

# CANCER GENOMICS & PROTEOMICS

[www.iar-anticancer.org](http://www.iar-anticancer.org), [www.iarjournals.org](http://www.iarjournals.org)

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004), VOL. 2 (2005), VOL. 3 (2006), VOL. 4 (2007),  
VOL. 5 (2008), VOL. 6 (2009), VOL. 7 (2010), VOL. 8 (2011)

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites [www.iar-anticancer.org](http://www.iar-anticancer.org) and [www.iarjournals.org](http://www.iarjournals.org).

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org) (Editorial Office); IAR websites: [www.iar-anticancer.org](http://www.iar-anticancer.org) and [www.iarjournals.org](http://www.iarjournals.org)

**Free specimen copies of CGP are available on request.**

## A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNYTSKYI (*Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia*)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DU-QUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (*Columbia, SC; St. Louis, MO, USA*)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (*Munich, Germany*)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (*Norcross, GA, USA; Guangzhou, P.R. China*)

TGF- $\beta$ 1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India*)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, J.-I. ISHII, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (*Kanagawa, Japan*)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O'MEARA, S. CRUET-HENNEQUART, M.P. CARTY (*Galway, Ireland*)

Identification of Melanoma Antigens Using a Serological Proteome Approach (SERPA). A. SUZUKI, A. IIZUKA, M. KOMIYAMA, M. TAKIKAWA, A. KUME, S. TAI, C. OHSHITA, A. KURUSU, Y. NAKAMURA, A. YAMAMOTO, N. YAMAZAKI, S. YOSHIKAWA, Y. KIYOHARA, Y. AKIYAMA (*Shizuoka; Tokyo; Saitama, Japan*)

DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (*Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA*)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (*Heidelberg; Mainz, Germany*)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (*Regensburg; Munich, Germany*)

## Experimental Studies